Growth Metrics

Eli Lilly (LLY) Cash & Current Investments (2016 - 2025)

Eli Lilly's Cash & Current Investments history spans 17 years, with the latest figure at $7.3 billion for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 112.34% year-over-year to $7.3 billion; the TTM value through Dec 2025 reached $7.3 billion, up 112.34%, while the annual FY2025 figure was $7.3 billion, 112.34% up from the prior year.
  • Cash & Current Investments reached $7.3 billion in Q4 2025 per LLY's latest filing, down from $9.9 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $9.9 billion in Q3 2025 to a low of $2.2 billion in Q4 2022.
  • Average Cash & Current Investments over 5 years is $3.7 billion, with a median of $3.2 billion recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: tumbled 43.41% in 2022, then surged 181.76% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $3.9 billion in 2021, then plummeted by 43.41% to $2.2 billion in 2022, then surged by 32.37% to $2.9 billion in 2023, then grew by 16.91% to $3.4 billion in 2024, then soared by 112.34% to $7.3 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Cash & Current Investments are $7.3 billion (Q4 2025), $9.9 billion (Q3 2025), and $3.5 billion (Q2 2025).